Taysha Gene Therapies
TSHA
52 hedge funds and large institutions have $43.8M invested in Taysha Gene Therapies in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 16 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
122% more call options, than puts
Call options by funds: $189K | Put options by funds: $85K
62% more capital invested
Capital invested by funds: $27M → $43.8M (+$16.8M)
2.87% less ownership
Funds ownership: 33.9% → 31.03% (-2.9%)
4% less funds holding
Funds holding: 54 → 52 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.81M |
| 2 |
TCM
Tybourne Capital Management
Hong Kong
|
+$2.02M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.72M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$982K |
| 5 |
AG
Artal Group
Luxembourg
|
+$810K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$651K |
| 2 |
D.E. Shaw & Co
New York
|
-$207K |
| 3 |
Two Sigma Advisers
New York
|
-$169K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$167K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$164K |
TSHA Hedge Fund Activity: Q4 2022 in Review
52 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2022, worth a combined $43.8M — up 62% from $27M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TSHA and 14 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 21 added.
The largest buyer was Nantahala Capital Management, adding an estimated $2.81M. The largest seller was BlackRock, cutting an estimated $651K.
- 52 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2022, down from 54 in Q3 2022.
- Funds reported $43.8M of Taysha Gene Therapies stock for Q4 2022, up 62% quarter-over-quarter.
- 14 funds opened new Taysha Gene Therapies positions in Q4 2022 and 16 closed out, a net change of -2 holders.
- The largest Taysha Gene Therapies buyer in Q4 2022 was Nantahala Capital Management, an estimated $2.81M added.
- The largest Taysha Gene Therapies seller in Q4 2022 was BlackRock, an estimated $651K sold.
Based on aggregated 13F filings for Q4 2022.